Why Is Praluent So Hard to Find? [Explained for 2026]

You've been prescribed Praluent (alirocumab) for high cholesterol or cardiovascular risk reduction — and now you're hitting a wall trying to fill it. If your pharmacy is telling you they don't have it, or if prior authorization has stalled your prescription for weeks, you're not alone. Here's an honest breakdown of why Praluent is so hard to access, and what steps you can take right now.

Is Praluent Actually in Short Supply?

The short answer: no — and that's what makes this so frustrating. Praluent (alirocumab) is NOT on the FDA drug shortage list, and its manufacturer, Regeneron/Sanofi, has not reported any manufacturing disruptions. The supply exists. The problem is getting it from the manufacturer to your hands.

Praluent's access challenges are a perfect storm of specialty pharmacy logistics, insurance bureaucracy, and cold-chain requirements — not a shortage in the traditional sense. Understanding each barrier is the first step to getting past them.

Why Most Retail Pharmacies Don't Stock Praluent

Walk into most CVS, Walgreens, or Walmart pharmacies and ask for Praluent — there's a good chance they won't have it. This isn't random. Several structural factors push Praluent out of retail settings:

Refrigeration requirements. Praluent must be stored between 36°F–46°F (2°C–8°C) and shipped in a cold chain. Retail pharmacies have limited cold-storage real estate and prefer high-turnover refrigerated products.

Low per-location prescription volume. PCSK9 inhibitors are prescribed to a relatively small subset of the population. A typical retail pharmacy may only dispense a handful of Praluent prescriptions per month — not enough to justify keeping inventory on hand.

High per-unit cost. Two Praluent pens cost $533–$777 per month at cash price. Holding that inventory represents a significant financial risk for individual pharmacy locations.

Specialty pharmacy channeling. Most insurance plans route specialty biologics like Praluent through designated specialty pharmacies — CVS Specialty, Walgreens Specialty, Accredo, or others — rather than retail locations.

Prior Authorization: The Biggest Bottleneck

Before your insurance will pay for Praluent, your doctor must submit a prior authorization (PA) request. This process can take days to weeks — and a significant number of initial requests are denied.

Most insurers require documentation of:

A diagnosis of established cardiovascular disease (ASCVD) OR familial hypercholesterolemia (HeFH or HoFH)

Documented use of maximally tolerated statin therapy

LDL-C remaining above the payer's threshold (often 70 mg/dL for ASCVD or 100 mg/dL for primary prevention FH) despite statin therapy

Some plans require a documented trial of ezetimibe (Zetia) before approving a PCSK9 inhibitor

Even when all documentation is submitted correctly, plans can deny coverage, and then appeal processes take additional time. One preventive cardiologist at Johns Hopkins described the situation as: "The biggest barrier to PCSK9 inhibitor access is no longer price. It is the administrative burden of prior authorization and appeals."

Formulary Competition: Your Plan May Prefer Repatha

Praluent and Repatha (evolocumab) are both PCSK9 inhibitors with nearly identical mechanisms and similar LDL-lowering efficacy. But insurance formularies often prefer one over the other — placing it on a lower tier or requiring the other be tried first. If your plan prefers Repatha, getting Praluent covered will involve extra steps, even if your doctor prescribes it specifically.

Conversely, some plans prefer Praluent — so it's worth checking your formulary to see if Praluent is your plan's preferred PCSK9 inhibitor. If it is, the prior auth process may go more smoothly.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

No Generic or Biosimilar Available

Praluent is a biologic medication — meaning it's made from living cells, not synthesized chemically. As of 2026, there is no generic or biosimilar version of alirocumab approved in the United States. This means patients have no lower-cost alternative to the brand-name product, and pharmacies cannot substitute a cheaper equivalent the way they can with small-molecule drugs.

What You Can Do Right Now

Even with these barriers, most patients who are clinically appropriate for Praluent can eventually get access. Here's how to move the process forward:

Contact your doctor's office. Ask them to submit or resubmit a prior authorization with complete documentation of your cardiovascular history, statin intolerance, and LDL-C levels.

Ask about specialty pharmacies. Your insurance plan's specialty pharmacy is the most likely place to find Praluent in stock and covered.

Apply for the MyPRALUENT Copay Card. Commercially insured patients can reduce their out-of-pocket cost to as little as $35–$50/month with a maximum of $3,500 in annual savings.

Use medfinder.

Use medfinder. medfinder.com calls pharmacies near you to check which ones can fill your Praluent prescription — saving you hours of phone calls.

Skip the calls, skip the stress.

Find Praluent In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

The Bottom Line

Praluent's difficulty isn't a supply problem — it's an access problem. Specialty pharmacy logistics, prior authorization hurdles, formulary restrictions, and cost all play a role. The good news: these barriers are navigable with persistence, the right documentation, and the right resources.

For more specific tips on locating Praluent at a pharmacy near you, read our guide on how to find Praluent in stock near you.